Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Reduction from Citizens Jmp

Integra LifeSciences (NASDAQ:IART) had its price objective cut by Citizens Jmp from $25.00 to $22.00 in a report released on Thursday morning,Benzinga reports. They currently have a market outperform rating on the life sciences company’s stock.

Other equities research analysts have also recently issued reports about the stock. Citigroup restated an “outperform” rating on shares of Integra LifeSciences in a research note on Thursday. Weiss Ratings lowered shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Truist Financial lowered their target price on shares of Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating on the stock in a research note on Wednesday, October 14th. JPMorgan Chase & Co. dropped their price target on shares of Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating on the stock in a research report on Thursday. Finally, UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target for the company. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $16.75.

Integra LifeSciences Stock Down 3.3%

IART opened at $11.91 on Thursday. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The stock has a market cap of $926.24 million, a P/E ratio of 70.06, a P/E/G ratio of 0.64 and a beta of 1.21. The stock’s 50 day moving average price is $15.31 and its 200 day moving average price is $15.56.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.03. Integra LifeSciences had a return on equity of 18.74% and a net margin of 0.79%. The firm had revenue of $411.18 million for the quarter, compared to the consensus estimate of $413.16 million. During the same quarter in the previous year, the business earned ($0.07) EPS. As a group, research analysts predict that Integra LifeSciences will post 2.34 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY acquired a new stake in Integra LifeSciences during the 2nd quarter worth about $61,766,000. Bank of America Corp DE lifted its stake in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after acquiring an additional 589,408 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Integra LifeSciences in the second quarter worth approximately $8,723,000. Access Investment Management LLC grew its position in Integra LifeSciences by 72.0% in the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after acquiring an additional 268,085 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its stake in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after purchasing an additional 211,774 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra’s third-quarter EPS beat analysts’ expectations, offering some support to the investment case despite the revenue shortfall. Integra Q3 2026 Earnings Call Transcript
• Positive Sentiment: Some analysts continue to see substantial upside if restructuring gains traction, product relaunches succeed and market conditions normalize. Citizens JMP maintained a “market outperform” rating, although it reduced its price target to $22 from $25. Citizens JMP Price Target
• Positive Sentiment: The stock’s depressed valuation could attract value-oriented investors if Integra can restore margins and cash-flow growth; one analysis expects EBITDA margins above 20% and potentially double-digit free-cash-flow margins over time. Integra LifeSciences Valuation Analysis
• Neutral Sentiment: Integra completed a $2.1 billion refinancing, but its revolving credit commitment declined by $700 million to $600 million. The transaction addresses near-term financing needs while highlighting investor concerns about leverage and financial flexibility. Integra Refinancing Analysis
• Negative Sentiment: Analysts broadly lowered their expectations: Truist cut its price target to $13 from $15 and kept a “hold” rating; Citigroup reduced its target to $14 and maintained “neutral”; and JPMorgan lowered its target to $14 from $17 while retaining an “underweight” rating. Truist Price Target
• Negative Sentiment: Investors remain concerned about flooding-related disruption, specialty surgical headwinds, tissue reconstruction weakness and refinancing risk, all of which could delay the turnaround and pressure future earnings. Integra Q3 Revenue Miss
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations related to Integra’s disclosures, adding legal and reputational uncertainty, although no wrongdoing has been established. Integra Securities Investigation

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.